東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Approaching complex diseases = netwo...

Bizzarri, Mariano.

FindBook

Google Book

Amazon

博客來

Approaching complex diseases = network-based pharmacology and systems approach in bio-medicine /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Approaching complex diseases/ edited by Mariano Bizzarri.
其他題名:	network-based pharmacology and systems approach in bio-medicine /
其他作者:	Bizzarri, Mariano.
出版者:	Cham :Springer International Publishing : : 2020.,
面頁冊數:	xvi, 483 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Drug development. -
電子資源:	https://doi.org/10.1007/978-3-030-32857-3
ISBN:	9783030328573

Approaching complex diseases = network-based pharmacology and systems approach in bio-medicine /
Approaching complex diseasesnetwork-based pharmacology and systems approach in bio-medicine /[electronic resource] :edited by Mariano Bizzarri. - Cham :Springer International Publishing :2020. - xvi, 483 p. :ill., digital ;24 cm. - Human perspectives in health sciences and technology,v.22661-8915 ;. - Human perspectives in health sciences and technology ;v.2..

This volume - for pharmacologists, systems biologists, philosophers and historians of medicine - points to investigate new avenues in pharmacology research, by providing a full assessment of the premises underlying a radical shift in the pharmacology paradigm. The pharmaceutical industry is currently facing unparalleled challenges in developing innovative drugs. While drug-developing scientists in the 1990s mostly welcomed the transformation into a target-based approach, two decades of experience shows that this model is failing to boost both drug discovery and efficiency. Selected targets were often not druggable and with poor disease linkage, leading to either high toxicity or poor efficacy. Therefore, a profound rethinking of the current paradigm is needed. Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggest that exquisitely selective compounds, compared with multitarget drugs, may exhibit lower than desired clinical efficacy. This appreciation of the role of polypharmacology has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity. Integrating network biology and polypharmacology holds the promise of expanding the current opportunity space for druggable targets.

ISBN: 9783030328573

Standard No.: 10.1007/978-3-030-32857-3doiSubjects--Topical Terms:

716904
Drug development.

LC Class. No.: RM301.25 / .A677 2020

Dewey Class. No.: 615.10724

Approaching complex diseases = network-based pharmacology and systems approach in bio-medicine /
LDR:02407nmm a2200325 a 4500 001 2217523
003 DE-He213
005 20200811093459.0
006 m d
007 cr nn 008maaau
008 201120s2020 sz s 0 eng d
020 $a 9783030328573 $q (electronic bk.)
020 $a 9783030328566 $q (paper)
024 7 $a 10.1007/978-3-030-32857-3 $2 doi
035 $a 978-3-030-32857-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25 $b .A677 2020
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615.10724 $2 23
090 $a RM301.25 $b .A652 2020
245 0 0 $a Approaching complex diseases $h [electronic resource] : $b network-based pharmacology and systems approach in bio-medicine / $c edited by Mariano Bizzarri.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a xvi, 483 p. : $b ill., digital ; $c 24 cm.
490 1 $a Human perspectives in health sciences and technology, $x 2661-8915 ; $v v.2
520 $a This volume - for pharmacologists, systems biologists, philosophers and historians of medicine - points to investigate new avenues in pharmacology research, by providing a full assessment of the premises underlying a radical shift in the pharmacology paradigm. The pharmaceutical industry is currently facing unparalleled challenges in developing innovative drugs. While drug-developing scientists in the 1990s mostly welcomed the transformation into a target-based approach, two decades of experience shows that this model is failing to boost both drug discovery and efficiency. Selected targets were often not druggable and with poor disease linkage, leading to either high toxicity or poor efficacy. Therefore, a profound rethinking of the current paradigm is needed. Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggest that exquisitely selective compounds, compared with multitarget drugs, may exhibit lower than desired clinical efficacy. This appreciation of the role of polypharmacology has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity. Integrating network biology and polypharmacology holds the promise of expanding the current opportunity space for druggable targets.
650 0 $a Drug development. $3 716904
650 0 $a Developmental pharmacology. $3 3310153
650 1 4 $a Pharmacology/Toxicology. $3 890953
650 2 4 $a Systems Biology. $3 928020
650 2 4 $a Oncology. $3 751006
650 2 4 $a Philosophy of Medicine. $3 894449
700 1 $a Bizzarri, Mariano. $3 3450804
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Human perspectives in health sciences and technology ; $v v.2. $3 3450805
856 4 0 $u https://doi.org/10.1007/978-3-030-32857-3
950 $a Biomedical and Life Sciences (Springer-11642)